Nadia El-Guendy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2763721/publications.pdf

Version: 2024-02-01

10 papers	560 citations	1163117 8 h-index	1474206 9 g-index
11 all docs	11 docs citations	11 times ranked	502 citing authors

#	Article	IF	CITATIONS
1	Combining Bevacizumab with knocked-down \hat{l}^2 -catenin reduces VEGF-A and Slug mRNA in HepG2 but not in Caco-2 cell lines. Current Molecular Medicine, 2021, 21, .	1.3	O
2	Suppression of macrophages- Induced inflammation via targeting RAS and PAR-4 signaling in breast cancer cell lines. Toxicology and Applied Pharmacology, 2019, 385, 114773.	2.8	11
3	Novel CYP1B1 mutations and a possible prognostic use for surgical management of congenital glaucoma. International Journal of Ophthalmology, 2019, 11, 607-614.	1.1	6
4	Mutational Hotspots in the Mitochondrial D-Loop Region of Cancerous and Precancerous Colorectal Lesions in Egyptian Patients. DNA and Cell Biology, 2011, 30, 899-906.	1.9	19
5	Potential problems inherent in cell-based stable NF-κB–GFP reporter systems. Molecular and Cellular Biochemistry, 2008, 312, 147-155.	3.1	9
6	Infection with Toxoplasma gondii results in dysregulation of the host cell cycle. Cellular Microbiology, 2008, 10, 1153-1165.	2.1	83
7	Apoptosis by Par-4 in cancer and neurodegenerative diseases. Experimental Cell Research, 2003, 283, 51-66.	2.6	122
8	Identification of a Unique Core Domain of Par-4 Sufficient for Selective Apoptosis Induction in Cancer Cells. Molecular and Cellular Biology, 2003, 23, 5516-5525.	2.3	150
9	Oncogenic Ras Sensitizes Cells to Apoptosis by Par-4. Journal of Biological Chemistry, 1999, 274, 29976-29983.	3.4	91
10	Negative regulation of Par-4 by oncogenic Ras is essential for cellular transformation. Oncogene, 1999, 18, 7115-7123.	5.9	69